PF 04929113

Known as: SNX-5422 Mesylate, PF04929113, SNX-5422 
The orally bioavailable mesylate salt of a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2014
012320062014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
BACKGROUND Although prostate cancer responds initially to androgen ablation therapies, progression to castration-resistant… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
BACKGROUND Heat shock protein (HSP)90 regulates the function of proteins responsible for cell growth and survival, is… (More)
Is this relevant?
2012
2012
Hsp90 is an abundant protein in mammalian cells. It forms several discrete complexes, each containing distinct groups of co… (More)
Is this relevant?
2011
2011
PURPOSE To determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic/pharmacodynamic profile of the Hsp90… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2011
2011
Small-molecule inhibitors of Hsp90 show promise in the treatment of castrate-resistant prostate cancer (CRPC); however, these… (More)
Is this relevant?
2011
2011
PURPOSE Prostate cancer responds initially to antiandrogen therapies; however, progression to castration-resistant disease… (More)
Is this relevant?
2010
2010
A chemoproteomics-based drug discovery strategy is presented that utilizes a highly parallel screening platform, encompassing… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Heat-shock protein 90 (Hsp90) acts as a molecular chaperone required for maintaining the conformational stability of client… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2009
2009
A novel class of heat shock protein 90 (Hsp90) inhibitors was developed from an unbiased screen to identify protein targets for a… (More)
Is this relevant?
2009
2009
Inhibition of Hsp90 has emerged as a therapeutic strategy to target NSCLC subtypes, which are refractory to epidermal growth… (More)
Is this relevant?